Drug Discovery for Parkinson's With Mutations in the GBA Gene

Plain-language summary

This study collects biological samples for drug discovery aimed at Parkinson's disease with mutations in the GBA gene. It enrolls people aged 18 and older who have Parkinson's disease, Gaucher disease, or are healthy controls. It is a sample-collection study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

New York Stem Cell Foundation Research Institute

Intervention

Biological Sample Collection

Start date

7/15/2022

Estimated completion

7/15/2025

Countries

United States

Related genes

Locations

• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age 18 years or older.
* Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
* Must provide written informed consent unless physical limitations preclude signing.

Exclusion Criteria:

* For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
* For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
* For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.